Antisenescence therapies for age-related bone loss: Target factors, medicines, biomedical materials

Abstract

Progress in living conditions and medical technology have extended the human life span such that population aging, and thus the development of multi-system degenerative diseases, has become a major problem in many countries. Bone is a metabolically dynamic tissue and bone aging is closely related to a shift in the balance between bone resorption and bone formation. The resulting loss of bone mass and bone mechanical properties in older adults place them at risk of injury and premature death. Cellular senescence occurs in response to endogenous and exogenous stresses that lead to permanent cell cycle arrest and, thus, to tissue degeneration and dysfunction. Senescence in the bone microenvironment, as occurs during aging, induces a decline in bone formation. Research into the treatment of bone aging has therefore focused on the senescence process. This review begins with a summary of the key events in cellular senescence and bone aging and then examines recent progress in the targeting of cellular senescence, both to treat aging-related bone diseases. Novel therapeutic agents, natural products, and innovative biomedical materials are considered. Our discussion concludes by considering areas of future research.

Keywords

biomedical materials / bone aging / cellular senescence / medicines / target factors

References

[1] World Population Prospects 2022: Summary of Results. United Nations; 2022.

[2] Farr JN, Khosla S. Cellular senescence in bone. Bone. 2019; 121: 121-133.

[3] Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology. 2021; 22(2): 165-187.

[4] Sfeir JG, Drake MT, Khosla S, Farr JN. Skeletal aging. Mayo Clin Proc. 2022; 97(6): 1194-1208.

[5] Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961; 25(3): 585-621.

[6] Di Micco R, Krizhanovsky V, Baker D, d'Adda Di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021; 22(2): 75-95.

[7] Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell. 2019; 179(4): 813-827.

[8] Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013; 75(1): 685-705.

[9] Muñoz-Espín D, Cañamero M, Maraver A, et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013; 155(5): 1104-1118.

[10] Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018; 128(4): 1208-1216.

[11] Pi C, Ma C, Wang H, et al. MiR-34a suppression targets nampt to ameliorate bone marrow mesenchymal stem cell senescence by regulating NAD+-Sirt1 pathway. Stem Cell Res Ther. 2021; 12(1): 271.

[12] Childs BG, Durik M, Baker DJ, Van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015; 21(12): 1424-1435.

[13] Khosla S, Farr JN, Tchkonia T, Kirkland JL. The role of cellular senescence in ageing and endocrine disease. Nat Rev Endocrinol. 2020; 16(5): 263-275.

[14] Liu S, Jia X, Hao J, et al. Tissue engineering of JAK inhibitor-loaded hierarchically biomimetic nanostructural scaffold targeting cellular senescence for aged bone defect repair and bone remolding. Adv Healthc Mater. 2023; 22: 2301798.

[15] Gordon J, Tye CE, Banerjee B, et al. LINC01638 sustains human mesenchymal stem cell self-renewal and competency for osteogenic cell fate. Sci Rep. 2023; 13(1): 20314.

[16] Davis C, Dukes A, Drewry M, et al. MicroRNA-183-5p increases with age in bone-derived extracellular vesicles, suppresses bone marrow stromal (Stem) cell proliferation, and induces stem cell senescence. Tissue Eng Part A. 2017; 23(21-22): 1231-1240.

[17] Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017; 23(9): 1072-1079.

[18] Lu Z, Zhang W, No YJ, et al. Baghdadite ceramics prevent senescence in human osteoblasts and promote bone regeneration in aged rats. ACS Biomater Sci Eng. 2020; 6(12): 6874-6885.

[19] Wei F, Neal CJ, Sakthivel TS, et al. Cerium oxide nanoparticles protect against irradiation-induced cellular damage while augmenting osteogenesis. Mater Sci Eng C. 2021; 126: 112145.

[20] Wang Z, Zhang X, Cheng X, et al. Inflammation produced by senescent osteocytes mediates age-related bone loss. Front Immunol. 2023; 14: 1114006.

[21] Li J, Karim MA, Che H, Geng Q, Miao D. Deletion of p16 prevents estrogen deficiency-induced osteoporosis by inhibiting oxidative stress and osteocyte senescence. Am J Transl Res. 2020 Feb 15; 12(2): 672-683.

[22] Zheng Y, Deng J, Wang G, et al. P53 negatively regulates the osteogenic differentiation in jaw bone marrow MSCs derived from diabetic osteoporosis. Heliyon. 2023; 9(4): e15188.

[23] Hu M, Xing L, Zhang L, et al. NAP1L2 drives mesenchymal stem cell senescence and suppresses osteogenic differentiation. Aging Cell. 2022; 21(2): e13551.

[24] Wu W, Fu J, Gu Y, Wei Y, Ma P, Wu J. JAK2/STAT3 regulates estrogen-related senescence of bone marrow stem cells. J Endocrinol. 2020; 245(1): 141-153.

[25] Wei Y, Fu J, Wu W, Ma P, Ren L, Wu J. Estrogen prevents cellular senescence and bone loss through Usp10-dependent p53 degradation in osteocytes and osteoblasts: the role of estrogen in bone cell senescence. Cell Tissue Res. 2021; 386(2): 297-308.

[26] Ji X, Chen H, Liu B, Zhuang H, Bu S. Chk2 deletion rescues Bmi1 deficiency-induced mandibular osteoporosis by blocking DNA damage response pathway. Am J Transl Res. 2023 Mar 15; 15(3): 2220-2232.

[27] Fan P, Pu D, Lv X, et al. Cav 1.3 damages the osteogenic differentiation in osteoporotic rats by negatively regulating Spred 2-mediated autophagy-induced cell senescence. J Cell Mol Med. 2020; 24(23): 13863-13875.

[28] Wu S, Han N, Zheng Y, Hu C, Lei Y. The role of Snf5 in the osteogenic differentiation potential during replicative senescence of rat mesenchymal stromal cells. Mech Ageing Dev. 2018; 171: 1-6.

[29] Xiao Y, Cai G, Feng X, et al. Splicing factor YBX1 regulates bone marrow stromal cell fate during aging. EMBO J. 2023; 42(9): e111762.

[30] Sun W, Qiao W, Zhou B, et al. Overexpression of Sirt1 in mesenchymal stem cells protects against bone loss in mice by FOXO3a deacetylation and oxidative stress inhibition. Metabolism. 2018; 88: 61-71.

[31] Li X, Feng L, Zhang C, Wang J, Wang S, Hu L. Insulin-like growth factor binding proteins 7 prevents dental pulp-derived mesenchymal stem cell senescence via metabolic downregulation of p21. Sci China Life Sci. 2022; 65(11): 2218-2232.

[32] Tian Y, Xu Y, Xue T, et al. Notch activation enhances mesenchymal stem cell sheet osteogenic potential by inhibition of cellular senescence. Cell Death Dis. 2017; 8(2): e2595-e2595.

[33] Xu JZ, Zhou YM, Zhang LL, et al. BMP9 reduces age-related bone loss in mice by inhibiting osteoblast senescence through Smad1-Stat1-P21 axis. Cell Death Discov. 2022; 8(1): 254.

[34] Gao J, Wang H, Shen J, et al. Mutual regulation between GDF11 and TET2 prevents senescence of mesenchymal stem cells. J Cell Physiol. 2023; 238(12): 2827-2840.

[35] Tsai TL, Li WJ. Identification of bone marrow-derived soluble factors regulating human mesenchymal stem cells for bone regeneration. Stem Cell Rep. 2017; 8(2): 387-400.

[36] Yang R, Zhang J, Li J, et al. Inhibition of Nrf2 degradation alleviates age-related osteoporosis induced by 1,25-Dihydroxyvitamin D deficiency. Free Radic Biol Med. 2022; 178: 246-261.

[37] Sun H, Qiao W, Cui M, et al. The polycomb protein bmi1 plays a crucial role in the prevention of 1,25(oh) 2 d deficiency-induced bone loss. J Bone Miner Res. 2020; 35(3): 583-595.

[38] Klabklai P, Phetfong J, Tangporncharoen R, Isarankura-Na-Ayudhya C, Tawonsawatruk T, Supokawej A. Annexin A2 improves the osteogenic differentiation of mesenchymal stem cells exposed to high-glucose conditions through lessening the senescence. Int J Mol Sci. 2022; 23(20): 12521.

[39] Wu G, Xu R, Zhang P, et al. Estrogen regulates stemness and senescence of bone marrow stromal cells to prevent osteoporosis via ERβ-SATB2 pathway. J Cell Physiol. 2018; 233(5): 4194-4204.

[40] Yu X, Zhang C, Ma Q, et al. SCD2 regulation targeted by mir-200c-3p on lipogenesis alleviates mesenchymal stromal cell senescence. Int J Mol Sci. 2024; 25(15): 8538.

[41] Yeo D, Zars Fisher EL, Khosla S, Farr JN, Westendorf JJ. Hdac3-deficiency increases senescence-associated distention of satellite DNA and telomere-associated foci in osteoprogenitor cells. J Bone Miner Res. 2024; 39(7): 994-1007.

[42] Yang Y, Yuan K, Liu Y, et al. Constitutively activated AMPKΑ1 protects against skeletal aging in mice by promoting bone-derived IGF -1 secretion. Cell Prolif. 2023; 56(10): e13476.

[43] Gao J, Wang H, Shen J, et al. Mutual regulation between GDF11 and TET2 prevents senescence of mesenchymal stem cells. J Cell Physiol. 2023; 238: jcp.31132.

[44] Patil VS, Zhou R, Rana TM. Gene regulation by non-coding RNAs. Crit Rev Biochem Mol Biol. 2014; 49(1): 16-32.

[45] Wu J, Lin T, Gao Y, et al. Long noncoding RNA ZFAS1 suppresses osteogenic differentiation of bone marrow-derived mesenchymal stem cells by upregulating miR-499-EPHA5 axis. Mol Cell Endocrinol. 2022; 539: 111490.

[46] Wang Q, Li Y, Zhang Y, et al. LncRNA MEG3 inhibited osteogenic differentiation of bone marrow mesenchymal stem cells from postmenopausal osteoporosis by targeting miR-133a-3p. Biomed Pharmacother. 2017; 89: 1178-1186.

[47] Park H, Park H, Pak HJ, et al. miR-34a inhibits differentiation of human adipose tissue-derived stem cells by regulating cell cycle and senescence induction. Differentiation. 2015; 90(4-5): 91-100.

[48] Mokhberian N, Bolandi Z, Eftekhary M, et al. Inhibition of miR-34a reduces cellular senescence in human adipose tissue-derived mesenchymal stem cells through the activation of SIRT1. Life Sci. 2020; 257: 118055.

[49] Fan J, An X, Yang Y, et al. MiR-1292 targets FZD4 to regulate senescence and osteogenic differentiation of stem cells in te/sj/mesenchymal tissue system via the Wnt/β-catenin pathway. Aging Dis. 2018; 9(6): 1103.

[50] Zhang L, Zhang C, Zheng J, et al. miR-155-5p/Bmal1 modulates the senescence and osteogenic differentiation of mouse bmscs through the hippo signaling pathway. Stem Cell Rev Rep. 2024; 20(2): 554-567.

[51] Ding Z, Ma G, Zhou B, et al. Targeting miR-29 mitigates skeletal senescence and bolsters therapeutic potential of mesenchymal stromal cells. Cell Rep Med. 2024; 5(8): 101665.

[52] Mei Q, Li K, Tang T, et al. MIR -203-3p promotes senescence of mouse bone marrow mesenchymal stem cells via downregulation of PBK. Aging Cell. 2024; 23(11): e14293.

[53] Qi L, Pan C, Yan J, et al. Mesoporous bioactive glass scaffolds for the delivery of bone marrow stem cell-derived osteoinductive extracellular vesicles lncRNA promote senescent bone defect repair by targeting the miR-1843a-5p/Mob3a/YAP axis. Acta Biomater. 2024; 177: 486-505.

[54] Qi L, Hong S, Zhao T, et al. DNA tetrahedron delivering miR-21-5p promotes senescent bone defects repair through synergistic regulation of osteogenesis and angiogenesis. Adv Healthc Mater. 2024;13: e2401275.

[55] Qi L, Fang X, Yan J, et al. Magnesium-containing bioceramics stimulate exosomal miR-196a-5p secretion to promote senescent osteogenesis through targeting Hoxa7/MAPK signaling axis. Bioact Mater. 2024; 33: 14-29.

[56] Kaur J, Saul D, Doolittle ML, Farr JN, Khosla S, Monroe DG. MicroRNA-19a-3p decreases with age in mice and humans and inhibits osteoblast senescence. JBMR Plus. 2023; 7(6): e10745.

[57] Yao C, Sun J, Luo W, et al. Down-expression of miR-494-3p in senescent osteocyte-derived exosomes inhibits osteogenesis and accelerates age-related bone loss via PTEN/PI3K/AKT pathway. Bone Jt Res. 2024; 13(2): 52-65.

[58] Zhou Y, Xin X, Wang L, et al. Senolytics improve bone forming potential of bone marrow mesenchymal stem cells from aged mice. Npj Regen Med. 2021; 6(1): 34.

[59] Wang Y, Che L, Chen X, et al. Repurpose dasatinib and quercetin: targeting senescent cells ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration. Bioact Mater. 2023; 25: 13-28.

[60] Yang N, Nakagawa M, Nishiura A, et al. Identification of senescent cells in peri-implantitis and prevention of mini-implant loss using senolytics. Int J Mol Sci. 2023; 24(3): 2507.

[61] Wang T, Yang L, Liang Z, et al. Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis. Signal Transduct Target Ther. 2021; 6(1): 143.

[62] Zhou Y, Al-Naggar IMA, Chen P, et al. Senolytics alleviate the degenerative disorders of temporomandibular joint in old age. Aging Cell. 2021; 20(7): e13394.

[63] Molagoda IMN, Kang CH, Lee MH, et al. Fisetin promotes osteoblast differentiation and osteogenesis through GSK-3β phosphorylation at Ser9 and consequent β-catenin activation, inhibiting osteoporosis. Biochem Pharmacol. 2021; 192: 114676.

[64] Hambright WS, Mu X, Gao X, et al. The senolytic drug fisetin attenuates bone degeneration in the zmpste24−/− progeria mouse model. J Osteoporos. 2023; 2023: 1-12.

[65] Chaib S, Tchkonia T, Kirkland JL. Cellular senescence and senolytics: the path to the clinic. Nat Med. 2022; 28(8): 1556-1568.

[66] Su W, Hu Y, Fan X, Xie J. Clearance of senescent cells by navitoclax (ABT263) rejuvenates UHMWPE-induced osteolysis. Int Immunopharmacol. 2023; 115: 109694.

[67] Sharma AK, Roberts RL, Benson RD, et al. The senolytic drug navitoclax (ABT-263) causes trabecular bone loss and impaired osteoprogenitor function in aged mice. Front Cell Dev Biol. 2020; 8: 354.

[68] Marycz K, Tomaszewski KA, Kornicka K, et al. Metformin decreases reactive oxygen species, enhances osteogenic properties of adipose-derived multipotent mesenchymal stem cells in vitro, and increases bone density in vivo. Oxid Med Cell Longev. 2016; 2016: 1-19.

[69] Zhou J, Wang L, Peng C, Peng F. Co-Targeting tumor angiogenesis and immunosuppressive tumor microenvironment: a perspective in ethnopharmacology. Front Pharmacol. 2022; 13: 886198.

[70] Wu Q, Lv Q, Liu X, et al. Natural compounds from botanical drugs targeting mTOR signaling pathway as promising therapeutics for atherosclerosis: a review. Front Pharmacol. 2023; 14: 1083875.

[71] Zhang Z, Deng T, Wu M, Zhu A, Zhu G. Botanicals as modulators of depression and mechanisms involved. Chin Med. 2019; 14(1): 24.

[72] Lv YJ, Yang Y, Sui BD, et al. Resveratrol counteracts bone loss via mitofilin-mediated osteogenic improvement of mesenchymal stem cells in senescence-accelerated mice. Theranostics. 2018; 8(9): 2387-2406.

[73] Zhou T, Yan Y, Zhao C, Xu Y, Wang Q, Xu N. Resveratrol improves osteogenic differentiation of senescent bone mesenchymal stem cells through inhibiting endogenous reactive oxygen species production via AMPK activation. Redox Rep. 2019; 24(1): 62-69.

[74] Ali D, Chen L, Kowal JM, et al. Resveratrol inhibits adipocyte differentiation and cellular senescence of human bone marrow stromal stem cells. Bone. 2020; 133: 115252.

[75] Varela-Eirín M, Carpintero-Fernández P, Sánchez-Temprano A, et al. Senolytic activity of small molecular polyphenols from olive restores chondrocyte redifferentiation and promotes a pro-regenerative environment in osteoarthritis. Aging. 2020; 12(16): 15882-15905.

[76] Heo JS, Lee SG, Kim HO. The flavonoid glabridin induces oct4 to enhance osteogenetic potential in mesenchymal stem cells. Stem Cells Int. 2017; 2017: 1-10.

[77] Ali D, Okla M, Abuelreich S, et al. Apigenin and Rutaecarpine reduce the burden of cellular senescence in bone marrow stromal stem cells. Front Endocrinol. 2024; 15: 1360054.

[78] Liu Z, Li Q, Wang X, et al. Proanthocyanidin enhances the endogenous regeneration of alveolar bone by elevating the autophagy of PDLSCS. J Periodontal Res. 2023; 58(6): 1300-1314.

[79] Wu Y, Wang X, Zhang Y, et al. Proanthocyanidins ameliorate LPS-inhibited osteogenesis of PDLSCs by restoring lysine lactylation. Int J Mol Sci. 2024; 25(5): 2947-2965.

[80] Wang Z, Jiang R, Wang L, et al. Ginsenoside Rg1 improves differentiation by inhibiting senescence of human bone marrow mesenchymal stem cell via GSK-3 β and β -Catenin. Stem Cells Int. 2020; 2020: 1-16.

[81] Hong T, Kim MY, Da Ly D, et al. Ca2+-activated mitochondrial biogenesis and functions improve stem cell fate in Rg3-treated human mesenchymal stem cells. Stem Cell Res Ther. 2020; 11(1): 467.

[82] Wang JY, Chen WM, Wen CS, SC Hung, Chen PW, Chiu JH. Du-Huo-Ji-Sheng-Tang and its active component ligusticum chuanxiong promote osteogenic differentiation and decrease the aging process of human mesenchymal stem cells. J Ethnopharmacol. 2017; 198: 64-72.

[83] Gao B, Lin X, Jing H, et al. Local delivery of tetramethylpyrazine eliminates the senescent phenotype of bone marrow mesenchymal stromal cells and creates an anti-inflammatory and angiogenic environment in aging mice. Aging Cell. 2018; 17(3): e12741.

[84] Chen W, Lv N, Liu H, et al. Melatonin improves the resistance of oxidative stress-induced cellular senescence in osteoporotic bone marrow mesenchymal stem cells. Maraldi T, ed. Oxid Med Cell Longev. 2022; 2022: 1-22.

[85] Xie Y, Han N, Li F, et al. Melatonin enhances osteoblastogenesis of senescent bone marrow stromal cells through NSD2-mediated chromatin remodelling. Clin Transl Med. 2022; 12(2): e746.

[86] Cui C, Zheng L, Fan Y, et al. Parathyroid hormone ameliorates temporomandibular joint osteoarthritic-like changes related to age. Cell Prolif. 2020; 53(4): e12755.

[87] Bhattarai G, So HS, Kim TG, et al. Astaxanthin protects against hyperglycemia-induced oxidative and inflammatory damage to bone marrow and to bone marrow-retained stem cells and restores normal hematopoiesis in streptozotocin-induced diabetic mice. Antioxidants. 2022; 11(12): 2321.

[88] Tang G, Ma H, Liu S, Wu J, Gong A. Pyrroloquinoline quinone inhibits ligature-induced alveolar bone loss through regulation of redox balance and cell senescence. Am J Transl Res. 2022; 14(1): 582-593.

[89] Shang L, Li X, Ding X, et al. S -Adenosyl- L -methionine alleviates the senescence of MSCs through the PI3K/AKT/FOXO3a signaling pathway. Stem Cells. 2024; 42(5): 475-490.

[90] Kou Y, Rong X, Tang R, et al. Eldecalcitol prevented OVX-induced osteoporosis through inhibiting BMSCs senescence by regulating the SIRT1-Nrf2 signal. Front Pharmacol. 2023; 14: 1067085.

[91] Zhu L, Luo D, Liu Y. Effect of the nano/microscale structure of biomaterial scaffolds on bone regeneration. Int J Oral Sci. 2020; 12(1): 6.

[92] Lu Z, Wang G, Roohani-Esfahani I, Dunstan CR, Zreiqat H. Baghdadite ceramics modulate the cross talk between human adipose stem cells and osteoblasts for bone regeneration. Tissue Eng Part A. 2014; 20(5-6): 992-1002.

[93] Chen S, Yu Y, Xie S, et al. Local H2 release remodels senescence microenvironment for improved repair of injured bone. Nat Commun. 2023; 14(1): 7783.

[94] Chen Q, Shou P, Zheng C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016; 23(7): 1128-1139.

[95] Zhou C, Chen YQ, Zhu YH, et al. Antiadipogenesis and osseointegration of strontium-doped implant surfaces. J Dent Res. 2019; 98(7): 795-802.

[96] Dong S, Zhao T, Wu W, et al. Sandblasted/Acid-Etched titanium surface modified with calcium phytate enhances bone regeneration in a high-glucose microenvironment by regulating reactive oxygen species and cell senescence. ACS Biomater Sci Eng. 2023; 9(8): 4720-4734.

[97] Chen M, Wang D, Li M, et al. Nanocatalytic biofunctional MOF coating on titanium implants promotes osteoporotic bone regeneration through cooperative pro-osteoblastogenesis MSC reprogramming. ACS Nano. 2022; 16(9): 15397-15412.

[98] Tampieri A, Sandri M, Iafisco M, et al. Nanotechnological approach and bio-inspired materials to face degenerative diseases in aging. Aging Clin Exp Res. 2021; 33(4): 805-821.

[99] Cawthray J, Wasan E, Wasan K. Bone-seeking agents for the treatment of bone disorders. Drug Deliv Transl Res. 2017; 7(4): 466-481.

[100] Kang DH, Park YS, Lee DY. Senotherapy for attenuation of cellular senescence in aging and organ implantation. J Ind Eng Chem. 2018; 60: 1-8.

[101] Xing X, Huang H, Gao X, et al. Local elimination of senescent cells promotes bone defect repair during aging. ACS Appl Mater Interfaces. 2022; 14(3): 3885-3899.

[102] Xing X, Tang Q, Zou J, et al. Bone-targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis. Acta Biomater. 2023; 157: 352-366.

[103] Wang Y, Xie F, He Z, et al. Senescence-Targeted and NAD + -Dependent SIRT1-Activated nanoplatform to counteract stem cell senescence for promoting aged bone regeneration. Small. 2023;20: e2304433.

[104] Xu Z, Zhang Y, Lu D, et al. Antisenescence ZIF-8/Resveratrol nanoformulation with potential for enhancement of bone fracture healing in the elderly. ACS Biomater Sci Eng. 2023; 9(5): 2636-2646.

[105] Li K, Hu S, Huang J, et al. Targeting ROS-induced osteoblast senescence and RANKL production by Prussian blue nanozyme based gene editing platform to reverse osteoporosis. Nano Today. 2023; 50: 101839.

[106] He Z, Sun C, Ma Y, et al. Rejuvenating aged bone repair through multihierarchy reaction oxygen species-regulated hydrogel. Adv Mater. 2023;36: e2306552.

[107] Wei F, Neal CJ, Sakthivel TS, et al. A novel approach for the prevention of ionizing radiation-induced bone loss using a designer multifunctional cerium oxide nanozyme. Bioact Mater. 2023; 21: 547-565.

[108] Farr JN, Kaur J, Doolittle ML, Khosla S. Osteocyte cellular senescence. Curr Osteoporos Rep. 2020; 18(5): 559-567.

[109] He X, Hu W, Zhang Y, et al. Cellular senescence in skeletal disease: mechanisms and treatment. Cell Mol Biol Lett. 2023; 28(1): 88.

[110] Wölfel EM, Fernandez-Guerra P, Nørgård MØ, et al. Senescence of skeletal stem cells and their contribution to age-related bone loss. Mech Ageing Dev. 2024; 221: 111976.

[111] Mattison JA, Colman RJ, Beasley TM, et al. Caloric restriction improves health and survival of rhesus monkeys. Nat Commun. 2017; 8(1): 14063-14075.

[112] Zhang G, Zhou X, Hu S, Jin Y, Qiu Z. Large animal models for the study of tendinopathy. Front Cell Dev Biol. 2022; 10: 1031638-1031650.

[113] Chen F, Wang B, Sun X, Wang Y, Wang R, Li K. Ergothioneine improves cognitive function by ameliorating mitochondrial damage and decreasing neuroinflammation in a D-galactose-induced aging model. Food Funct. 2024; 15(23): 11686-11696.

[114] Habieb ME, Mohamed MA, El Gamal DM, Hawas AM, Mohamed TM. Anti-aging effect of DL-β-hydroxybutyrate against hepatic cellular senescence induced by D-galactose or γ-irradiation via autophagic flux stimulation in male rats. Arch Gerontol Geriatr. 2021; 92: 104288-104301.

[115] Dorado B, Pløen GG, Barettino A, et al. Generation and characterization of a novel knockin minipig model of hutchinson-gilford progeria syndrome. Cell Discov. 2019; 5(1): 16-31.

[116] Chen S, Chen X, Geng Z, Su J. The horizon of bone organoid: a perspective on construction and application. Bioact Mater. 2022; 18: 15-25.

[117] Bai L, Zhou D, Li G, Liu J, Chen X, Su J. Engineering bone/cartilage organoids: strategy, progress, and application. Bone Res. 2024; 12(1): 66.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.